Nkarta (NASDAQ:NKTX) CEO Paul Hastings Sells 26,046 Shares

Nkarta, Inc. (NASDAQ:NKTX) CEO Paul Hastings sold 26,046 shares of the stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $2.07, for a total value of $53,915.22. Following the transaction, the chief executive officer directly owned 390,023 shares of the company’s stock, valued at $807,347.61. This trade represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Nkarta Price Performance

NASDAQ NKTX remained flat at $2.04 during trading on Tuesday. The company’s stock had a trading volume of 357,832 shares, compared to its average volume of 794,083. The firm’s fifty day simple moving average is $1.88 and its 200 day simple moving average is $2.03. Nkarta, Inc. has a 1 year low of $1.31 and a 1 year high of $2.74. The firm has a market capitalization of $144.90 million, a PE ratio of -1.48 and a beta of 0.60.

Nkarta (NASDAQ:NKTX) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.03. On average, analysts forecast that Nkarta, Inc. will post -1.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on NKTX. Weiss Ratings restated a “sell (d-)” rating on shares of Nkarta in a research report on Monday, December 29th. Wall Street Zen raised shares of Nkarta from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Finally, Stifel Nicolaus lowered their price objective on shares of Nkarta from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, November 11th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $13.25.

Institutional Trading of Nkarta

Hedge funds and other institutional investors have recently modified their holdings of the business. Invesco Ltd. increased its holdings in Nkarta by 478.4% during the 1st quarter. Invesco Ltd. now owns 69,396 shares of the company’s stock worth $128,000 after acquiring an additional 57,399 shares during the period. AQR Capital Management LLC lifted its stake in Nkarta by 300.5% in the first quarter. AQR Capital Management LLC now owns 672,078 shares of the company’s stock worth $1,237,000 after purchasing an additional 504,272 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Nkarta by 13.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 681,068 shares of the company’s stock valued at $1,253,000 after acquiring an additional 80,211 shares during the period. Jane Street Group LLC grew its holdings in shares of Nkarta by 118.7% in the first quarter. Jane Street Group LLC now owns 134,286 shares of the company’s stock worth $247,000 after purchasing an additional 852,559 shares during the last quarter. Finally, CWM LLC increased its position in shares of Nkarta by 23.4% in the second quarter. CWM LLC now owns 34,758 shares of the company’s stock valued at $58,000 after acquiring an additional 6,601 shares during the period. Institutional investors own 80.54% of the company’s stock.

Nkarta Company Profile

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.